ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 diabetes in children and adolescents.

OF WHAT IS NEW/DIFFERENT Updates since the 2022 ISPAD guidelines on this topic include: • Diagnostic algorithm for youth with new onset type 2 diabetes (T2D). • Algorithms and tables for treatment, management, and assessment of co-morbidities and complications. • Recommendations on recently approved pharmacologic therapies for the treatment of youth-onset T2D and management strategies.

Prescription Fills Among Patients With Type 2 Diabetes After Hospitalization for Acute Coronary Syndrome.

Importance: Individuals with type 2 diabetes (T2D) have high rates of mortality following myocardial infarction (MI). Hospitalization is an opportunity to initiate or continue evidence-based treatment to reduce risk in individuals with T2D and acute coronary syndrome (ACS).

Objective: To determine patterns of evidence-based medication use during the period of transition from admission to discharge after hospitalization for MI or coronary revascularization among individuals with T2D and ACS.

Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial.

Background: Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, has been shown to reduce hunger and weight in patients aged 6 years and older with proopiomelanocortin (POMC) deficiency (including biallelic variants in proprotein convertase subtilisin/kexin type 1 [PCSK1]), leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS). No approved therapies for patients younger than 6 years old currently exist. The phase 3, open-label VENTURE trial aimed to evaluate the efficacy and safety of setmelanotide in patients aged 2-5 years with POMC or LEPR deficiency or BBS.

TE-Seq: A Transposable Element Annotation and RNA-Seq Pipeline.

Motivation: The recognition that transposable elements (TEs) play important roles in many biological processes has elicited growing interest in analyzing sequencing data derived from this 'dark genome'. This is however complicated by the highly repetitive nature of these sequences in genomes, requiring the deployment of several problem-specific tools as well as the curation of appropriate genome annotations. This pipeline aims to make the analysis of TE sequences and their expression more generally accessible.